Breaking AI & Tech News Analyzed

Podcast Overview: Red‑Light Masks and Ageing ClaimsThe Guardian’s latest science podcast asks the question, “Is it true that red‑light therapy masks prevent wrinkles?” It invites listeners to explore the evidence behind a popular anti‑ageing gadget.What the Episode CoversIntroduction to red‑light therapy and its purported skin‑benefits.Interviews with dermatologists and researchers discussing clinical findings.Consumer perspectives on the rise of at‑home light‑mask devices.Current Evidence LandscapeWhile some small studies suggest modest improvements in skin texture, the podcast notes the lack of large‑scale, peer‑reviewed trials confirming long‑term wrinkle reduction.Implications for Consumers and the Beauty IndustryThe discussion highlights a growing market for home‑use light devices, prompting regulators to consider clearer labelling and efficacy standards.Looking Ahead: Research and RegulationFuture episodes may track upcoming clinical trials and potential guidance from health authorities on the safe use of red‑light masks.

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

GLP‑1 Medications Show Promise in Reducing Breast Cancer IncidenceRecent analyses presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago suggest that patients using GLP‑1 receptor agonists—a class of weight‑loss drugs—experienced a 30% lower likelihood of being diagnosed with breast cancer compared with non‑users.Study cohort: 110,000 women aged 45‑80.Risk reduction: 30% for breast cancer onset.Lead researcher: Dr Elizabeth McDonald, University of Pennsylvania.Adjunctive Use of GLP‑1 Drugs Cuts Breast Cancer MortalityA separate investigation involving 27,000 breast‑cancer patients in Italy reported that adding a GLP‑1 agent to standard therapy was associated with a 30% decrease in cancer‑related death.Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.Outcome: 30% lower mortality risk.Broad Cancer‑Spread Benefits Observed Across Multiple Tumor TypesData from the Cleveland Clinic, covering 12,000 patients with breast, lung, colorectal or liver cancer, indicated a 38‑50% reduction in progression to stage‑four disease among GLP‑1 users.Study size: 12,000 patients.Risk reduction range: 38%–50% for metastatic spread.Why These Findings Matter for Public Health and OncologyThe consistency of risk‑reduction signals across incidence, mortality and metastasis points to a potential paradigm shift: drugs originally designed for diabetes and obesity may become adjunct tools in cancer prevention and treatment. If confirmed, the impact could be substantial given the prevalence of obesity and the high incidence of breast cancer worldwide.Next Steps: Clinical Trials and Regulatory ConsiderationsExperts caution that the current evidence is observational. Ongoing randomized controlled trials will be needed to disentangle the effects of weight loss from direct pharmacologic actions of GLP‑1 agonists. Regulatory bodies may eventually evaluate these agents for oncologic indications, pending robust trial data.

The Rise of Sound Baths Sound baths, a wellness trend where participants lie down or sit while practitioners play instruments like gongs and singing bowls, have become increasingly popular. Proponents claim that these experiences can "soothe and calm your nervous system" and promote "healing" through specific sound frequencies. Can Sound Baths Really Relax Us? Research suggests that sound baths can have a positive impact on mood and stress levels. A 2016 study found that participants who took part in a meditation session involving Tibetan singing bowls reported feeling less tension, anger, and fatigue. Another study linked Tibetan sound meditation to improved cognitive function and mental health in breast cancer patients. The Science Behind Sound and Emotion Experts agree that the effects of sound on wellbeing are largely related to how we perceive and interpret those sounds, rather than specific types or frequencies. Our breathing can synchronise with beats we hear, a phenomenon known as "rhythmic entrainment," and music can induce different emotions such as happiness, sadness, and fear. A Nice Experience or Music Therapy? While sound baths can be a "nice experience," experts caution that they should not be confused with music therapy, a regulated profession that uses music listening or production to improve psychological and physical health. Music therapists work with a range of clients, including in schools and hospitals, and there is no single equivalent regulatory body for sound bath practitioners. The Verdict In conclusion, while sound baths may have some benefits, experts agree that their effects can be overstated. Focusing on one thing and trying to quiet the mind is key to their potential benefits. As with any wellness trend, it's essential to approach sound baths with a critical and nuanced perspective.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Lead: New Hope for Brain Injury RecoveryDr. Orlando Swayne, a consultant neurologist at the National Hospital for Neurology and Neurosurgery in London, is challenging the long-held medical belief that broken brains cannot mend. Through his pioneering work in neurorehabilitation, Swayne demonstrates that the brain's remarkable capacity for neuroplasticity can lead to meaningful recovery even years after severe brain injuries, offering new hope to patients who were once considered beyond help.The Case of Claire: A Journey from Severe Impairment to RecoveryClaire, a mother of three in her late 30s, experienced life-changing trauma when an artery at the base of her brain ruptured, causing severe damage to her frontal lobe. Initially brought to the ward on a stretcher, she was unable to speak, with flat eyes and an expressionless face. While she could move her right arm slightly, her left arm and both legs were immobile. When asked if she had any questions, she wrote with a clenched pencil: "Questions, questions, questions," revealing characteristic signs of brain damage through pathological repetition.The Science of Neuroplasticity: How the Brain Heals ItselfThe key to recovery lies in the brain's capacity for neuroplasticity—its ability to make new connections and reorganize in the face of changed circumstances. After a stroke or brain injury, chemical changes in the brain trigger neuronal growth processes that were last active during development. Surviving neurons are spurred into making new connections to work around dead tissue. While this process occurs naturally, targeted therapy can significantly enhance and guide it, leading to more substantial functional improvements.The Critical Window for Recovery: Timing MattersWhile the brain's capacity for plasticity is greatest in the first few months after injury, research shows that neuroplasticity doesn't simply switch off. In one study, intensive therapy improved upper limb movement in patients 18 months after their strokes. This finding is crucial as it extends the potential for recovery beyond the traditional "golden window" of the first few weeks or months, offering hope to those who may have missed early intervention opportunities.The Moral and Economic Imperative of NeurorehabilitationStroke is a leading cause of adult disability in the UK, with approximately 12 million people globally suffering a stroke each year, and one in five dying within 30 days. The economic and human costs of untreated brain injuries are enormous. Swayne argues that providing early, targeted, and intense therapy is not just a moral obligation but also an economic imperative, as proper rehabilitation can significantly reduce long-term care costs while dramatically improving patients' quality of life and independence.The Future of Brain Injury Treatment: Balancing Hope with RealismWhile Swayne emphasizes that recovery is possible, he is careful to balance hope with realism. "There is hope, but clearly you have to balance that. Some people just don't recover," he acknowledges. His approach represents a middle ground between the false promises of miracle cures and the previous hopelessness surrounding brain injuries. By focusing on evidence-based interventions and realistic expectations, Swayne and his colleagues are transforming the landscape of neurorehabilitation, offering meaningful improvements even for those with the most severe impairments.

Lionel Messi was the sole figure on the pitch during Argentina’s inaugural World Cup training session at their Kansas City base, a clear sign that the squad is meticulously managing fitness concerns ahead of the tournament. Solo Session Highlights Messi’s Fitness Focus The defending champions held their first pre‑tournament training on Monday, with the 38‑year‑old captain working on “specific exercises” while teammates with similar niggles joined physiotherapy staff. Messi has been coping with left hamstring fatigue since May 24, but the Argentine Football Association remains confident he will be ready for the opening match against Algeria on June 16 in Kansas City. Key Numbers Behind the Preparation Age: 38 International caps: 198 (all‑time Argentine leader) Goals for Argentina: 116 (all‑time record) Hamstring issue since: May 24 Next competitive match: June 9 vs Iceland (tune‑up in Auburn, Alabama) World Cup opener: June 16 vs Algeria Strategic Implications for Argentina’s Campaign By isolating Messi for targeted work, the coaching staff signals a dual strategy: preserve the star’s health while allowing the broader squad to maintain collective training intensity. This approach aims to minimize the risk of aggravating Messi’s hamstring, which could jeopardize Argentina’s attacking potency in a tournament where they are ranked #3 globally. Outlook: Messi’s Readiness and Argentina’s Prospects If Messi clears his fitness hurdle, Argentina enters the group stage with a fully fit talisman, boosting both morale and tactical flexibility. Conversely, any setback could force the team to rely more heavily on emerging talents, testing the depth built around Messi’s experience. The next week’s tune‑up against Iceland will serve as a litmus test for the squad’s overall health and cohesion.

Court Blocks Trump's Transgender Military BanA United States court of appeals has ruled that a policy under President Donald Trump to expel transgender troops from the military was a violation of the Constitution. Monday's decision was a split one among the three-judge panel of the US appeals court for the District of Columbia.One judge, Robert Wilkins, an appointee of former Democratic President Barack Obama, upheld a lower court ruling rejecting the Trump administration's policy as it pertains to already enlisted service members. A second judge – Judith Rogers, who was picked by former Democratic President Bill Clinton – agreed with his opinion, but only in part. She felt it should extend to those who seek to enlist, too.And the third judge, Trump pick Justin Walker, issued a dissent questioning the court's ability to second-guess US military policy.Origins of Trump's Controversial PolicyThe case focused on one of the earliest actions Trump took during his second term in office. On January 27, 2025, a week after his second inauguration, Trump issued an executive order called "Prioritizing Military Excellence and Readiness".In it, he denounced the US armed forces as having been infiltrated with "radical gender ideology". He proceeded to describe transgender people as unfit for service for embracing a "false 'gender identity'"."A man's assertion that he is a woman, and his requirement that others honor this falsehood, is not consistent with the humility and selflessness required of a service member," Trump wrote.The executive order became the basis for a 13-page Pentagon memorandum, issued in February 2025 under Defense Secretary Pete Hegseth. It declared that any service member who has "symptoms" of gender dysphoria, or who has used hormone therapy or surgery to affirm their gender, would be "disqualified from military service".Military Service Record of Transgender PlaintiffsIn Monday's ruling, Wilkins described the policy as blatantly discriminatory. The policy, he wrote, "appears to be driven by the bare desire to harm a politically unpopular group: persons who identify as transgender"."To add insult, the President labeled transgender persons as dishonorable, undisciplined, arrogant, selfish liars," Wilkins added, pointing to the executive order.He pointed out that the transgender plaintiffs in the case had a combined 130 years of military service and had earned more than 80 commendations for their work.In the face of such evidence, Wilkins said the Trump administration had "forfeited any argument" that "retaining these service members will harm national security".Divided Rulings and Legal ImplicationsBut Wilkins stopped short of fully upholding a lower court ruling against the policy. Previously, Judge Ana Reyes had issued a temporary injunction against Trump's executive order, finding that the discrimination against transgender troops was unconstitutional.Wilkins agreed with Reyes that the Trump administration could not dismiss those already in the military's employ. But, he added, the harm was less for those seeking to enlist.Monday's ruling, therefore, strikes down the part of Reyes's injunction that would have barred the Trump administration from banning transgender people from the enlistment process.Rogers, the Clinton appointee, disagreed with that distinction. She pointed to testimony indicating that excluding transgender recruits from joining the military would deprive "our force of qualified personnel who have proven their ability to serve".Meanwhile, the dissent from the Trump appointee, Walker, hinged on his argument that the court had violated the separation of powers in the US government.Courts, he argued, should not be able to rule on the composition of the military."We have neither the expertise nor the authority to decide whether the military can exclude the plaintiffs from its ranks," Walker wrote. "The Constitution assigns that authority to Congress and the Commander in Chief."What Happens Next in the Legal BattleThe split decision is unlikely to have an immediate effect on US military policy. The appeals court has stayed the preliminary injunction from Reyes, as the legal fight continues, and last year, the US Supreme Court also halted an injunction against Trump's anti-transgender policy, in the case United States v Shilling.In a short, four-word social media post, Hegseth signalled that the Pentagon would appeal Monday's decision."See you at SCOTUS," he wrote, using the acronym for Supreme Court of the United States.But Democrats and LGBTQ+ advocates hailed the ruling as a victory against prejudice and discrimination in the Trump administration."No one who is qualified and answers the call to serve should be denied that opportunity because of who they are," US Representative John Larson of Connecticut wrote in a statement."Trump's trans military ban is discrimination — plain and simple. We'll keep fighting these attacks on our troops and all transgender Americans."